GMAB — Genmab A/S stock price, charts and financials

QT66Genmab A/S

Genmab A/S (NASDAQ: GMAB) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
30.87
-0.38-1.22%
OverviewShort InterestFilings
GMABQT66Genmab A/S·NASDAQ
30.87-1.22%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
BBIO+0.22%$84.67NBIX+0.92%$164.92JAZZ-0.02%$256.52ASND+0.08%$255.62UTHR-1.70%$529.66BNTX-0.93%$92.80MRNA+1.08%$59.81INCY+0.82%$121.55
Snapshot
Index-P/E23.24EPS (ttm)1.34Insider Own-Shs Outstand613.94MPerf Week8.24%
Market Cap18.98BForward P/E18.65EPS next Y1.68Insider Trans-Shs Float606.43MPerf Month4.94%
Enterprise Value22.81BPEG-EPS next Q-Inst Own-Short Float1.25%Perf Quarter15.48%
Income821.65MP/S2.02EPS this Y-14.34%Inst Trans-Short Ratio3.84Perf Half Y0.90%
Sales9.41BP/B3.34EPS next Y48.16%ROA6.64%Short Interest7.56MPerf YTD1.46%
Book/sh-P/C20.99EPS next 5Y24.26%ROE14.55%52W High35.00 -11.80%Perf Year45.28%
Cash/sh-P/FCF21.71EPS past 3/5Y-42.87% -26.58%ROIC8.91%52W Low20.74 48.81%Perf 3Y-21.05%
Dividend Est.-EV/EBITDA16.17Sales past 3/5Y-36.45% -18.11%Gross Margin38.74%Volatility2.62% 2.37%Perf 5Y-30.65%
Dividend TTM-EV/Sales2.42EPS Y/Y TTM-89.13%Oper. Margin13.69%ATR (14)0.88Perf 10Y76.85%
Dividend Ex-Date-Quick Ratio2.17Sales Y/Y TTM-81.88%Profit Margin8.72%RSI (14)72.95Recom2.33
Dividend Gr. 3/5Y-Current Ratio2.18EPS Q/Q-71.94%SMA207.88%Beta0.83Target Price39.08
Payout0.00%Debt/Eq0.94Sales Q/Q756.19%SMA5014.44%Rel Volume1.71Prev Close31.25
Employees3,088LT Debt/Eq0.88EarningsNov 05SMA2007.81%Avg Volume2.05MPrice30.87
IPO DateJun 01, 2009Option/ShortYes / YesEPS/Sales Surpr.-44.13% -1.08%Net Debt/EBITDA2.72Volume3,507,360Change-1.22%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-22-26ReiteratedNew Street$43
Jul-22-26UpgradeTD CowenHold → Buy
May-27-26ReiteratedTruist FinancialBuy$48 → $40
Apr-30-26ReiteratedHC Wainwright & Co.Buy$39 → $38
Mar-26-26InitiatedWolfe ResearchOutperform$32
Feb-23-26ReiteratedGuggenheimBuy$43 → $40
Feb-17-26ResumedJefferiesBuy$42
Jan-20-26ReiteratedHC Wainwright & Co.Buy$40 → $39
Oct-06-25ReiteratedTruist FinancialBuy$46 → $49
Oct-02-25ReiteratedHC Wainwright & Co.Buy$50 → $40
Latest News
Aug-07-26
Aug-07-2608:14AM
Genmab A/S (GMAB) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-06-26
Aug-06-2602:04PM
Genmab A/S Q2 Earnings Call Highlightsmarketbeat.com
Aug-03-26
Aug-03-2610:05AM
AbbVie: Strong Q2 And New Catalysts Keep Me BullishSeekingAlpha
Aug-01-26
Aug-01-2603:49AM
Avidity Partners Management LP Cuts Stock Holdings in Genmab A/S Sponsored ADR $GMABdefenseworld.net
Jul-28-26
Jul-28-2602:38AM
Genmab's H1 Preview: Darzalex Beats The Sales Outlookseekingalpha.com
Jul-23-26
Jul-23-2604:00PM
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)businesswire.com
Jul-22-26
Jul-22-2601:28PM
TD Cowen Upgrades Genmab to Buy, Raises Price Target to $43Benzinga
11:34AM
Genmab: Multiple Late-Stage Readouts Aheadseekingalpha.com
08:04AM
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Altria, Circle Internet, Coreweave, Digital Ocean, IBM, Keel Infrastructure, Nebius Group, Trimble, Vornado Realty, and More247wallst.com
Jul-15-26
Jul-15-2606:25AM
Genmab Reports Q2 DARZALEX Net Sales Of $4.207B, Up 17.6% YoYBenzinga
06:22AM
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026globenewswire.com
Jul-07-26
Jul-07-2612:15PM
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphomazacks.com
Jul-06-26
Jul-06-2601:59PM
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphomaglobenewswire.com
01:51PM
Genmab’s TEPKINLY + R2 Wins EU Approval As First Bispecific Therapy For Relapsed Follicular Lymphoma Following Phase 3 Trial SuccessBenzinga
Jun-30-26
Jun-30-2612:31PM
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunitybenzinga.com
Company

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,9013,72321,526——————
Cost of Goods Sold Incl. D&A261309985——————
Gross Profit3,6403,41420,541——————
Selling, General and Administrative Excl. Other6666023,790——————
Research and Development1,6871,5609,748——————
Other Operating Expense01300——————
Operating Income1,2871,2516,703——————
Interest Expense16861120——————
Unusual Expense
—————————
Non-Operating Income (Expense)-85152,581——————
Net Income Before Taxes1,0341,2059,164——————
Income Taxes2132411,320——————
Consolidated Net Income8219647,844——————
Net Income From Continuing Operations8219647,844——————
Net Income8219647,844——————
EPS (Recurring)1.331.5512.14——————
EPS (Basic, Before Extraordinaries)1.331.5512.14——————
EPS (Diluted)1.321.5412.14——————
EBITDA1,2371,3379,697——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio23.3920.001.72——————
Price To Sales Ratio4.865.150.63——————
Gross Margin93.3191.7095.42——————
Operating Margin32.9933.6031.14——————
Net Margin21.0525.8936.44——————
Shares Outstanding614622646——————
Market Capitalization18,95419,15813,482——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.